-
All Resources
(choose a category)
-
All Resources
-
selected
Evidence
Evidence, advice, guidance and standards
-
Improvement
Improvement and implementation support
-
Scrutiny
Assurance, scrutiny, measurement and reporting
-
-
Healthcare Area
- Dermatology
- Musculoskeletal system
-
Resource Type
- NICE Guidance
- Programme
- Year
- Page 1 of 1
5 results found filtered by Evidence Remove Evidence Filter 2010 Remove 2010 Filter 2009 Remove 2009 Filter 2004 Remove 2004 Filter Musculoskeletal system Remove Musculoskeletal system Filter NICE Guidance Remove NICE Guidance Filter Clear Search
-
Appraisal Guidance No. 204 Denosumab for the prevention of osteoporotic fractures
- Published
- 27 October 2010
- Cycle of Improvement
- Evidence
-
Appraisal Guidance No 195 – Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid
- Published
- 25 August 2010
- Cycle of Improvement
- Evidence
-
Appraisal Guidance No 199 – Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis
- Published
- 25 August 2010
- Cycle of Improvement
- Evidence
-
Appraisal Guidance No 198 – Tocilizumab for the treatment of rheumatoid arthritis
- Published
- 25 August 2010
- Cycle of Improvement
- Evidence
-
Appraisal Guidance No 186 – Certolizumab pegol for the treatment of rheumatoid arthritis
- Published
- 24 February 2010
- Cycle of Improvement
- Evidence